Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
| Status: | Unknown status |
|---|---|
| Conditions: | Healthy Studies, Migraine Headaches |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 21 - 50 |
| Updated: | 10/14/2017 |
| Start Date: | March 2013 |
The placebo effect is a phenomenon that has experienced major advances of its understanding
in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have
yet to be compared to healthy subjects. The investigators study aims to investigate the
magnitude of placebo response and related opioid release in patients that suffer from
episodic migraines as compared to healthy controls. In particular, the investigators are
looking to map brain activity during placebo analgesia using modern brain imaging techniques
such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET).
The investigators hypothesis is that placebo response and the availability of opioid
receptors is reduced in chronic migraine patients.
in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have
yet to be compared to healthy subjects. The investigators study aims to investigate the
magnitude of placebo response and related opioid release in patients that suffer from
episodic migraines as compared to healthy controls. In particular, the investigators are
looking to map brain activity during placebo analgesia using modern brain imaging techniques
such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET).
The investigators hypothesis is that placebo response and the availability of opioid
receptors is reduced in chronic migraine patients.
Inclusion Criteria:
- Migraine patients with aura with acute episodic migraine meeting the IHS
Classification ICHD-II criteria, 3-14 migraines per month.
- History of episodic migraine for at least 3 years
- Ages 21-50
- Male or Female
- Right Handed
Matched healthy subjects will also be recruited.
Exclusion Criteria:
- Other significant disease (systemic or CNS)
- Pregnancy
- Claustrophobia
- Weight >235 lbs (limit of MRI table)
- Significant drug including alcohol history (> 7 glasses of alcohol per week)
- Beck Depression Inventory II (BDI-II) score > 25 (moderate to severe depression)
- Any metal implants incompatible with MRI (including dental bridges, crowns, retainers,
orthodontic devices e.g. braces, IUDs, aneurysm clips or other devices, tattoos
containing metallic ink, cardiac pacemakers, prosthetic hear valves, other prostheses,
neurostimulator devices, implanted infusion pumps, exposure to shrapnel or metal
filings, cochlear implants, etc.)
- Previous significant research related exposure to ionizing radiation.
- History of allergy or adverse reaction to opioids
- Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac
disease including coronary artery disease, psychiatric problems; drug addiction,
respiratory problems, liver disease, etc.
- Positive drug of abuse screen (excluding medications currently prescribed for their
clinical condition, e.g. opioids, benzodiazepines, etc.)
- Patients with migraine <72 hours prior to the experiments will not be included to
ensure inter-ictal state.
- Opioids or preventative medication such as topiramate, SSRIs etc.
We found this trial at
1
site
Click here to add this to my saved trials
